SESN1 and cardiac hypertrophy: Preclinical studies have demonstrated that Sestrin-1 overexpression can attenuate pathological cardiac hypertrophy and improve vascular function.8 Translational studies are needed to determine whether enhancing Sestrin-1 activity could reduce cardiovascular risk in r-axSpA.